ResearchMoz

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014

Global Markets Direct
Published Date » 2014-02-28
No. Of Pages » 263
 Global Markets Direct’s, ‘Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer’s therapeutic pipeline. 
   
 This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic...
Table of Content

Introduction
Global Markets Direct Report Coverage
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
Genentech, Inc.
Bavarian Nordic A/S
Emergent BioSolutions Inc.
Takeda Pharmaceutical Company Limited
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
GTx, Inc.
Teva Pharmaceutical Industries Limited
Progenics Pharmaceuticals, Inc.
Exelixis, Inc.
Onyx Pharmaceuticals, Inc.
Merck KGaA
Active Biotech AB
Oncolytics Biotech Inc.
Oncothyreon Inc.
Medivation, Inc.
Synta Pharmaceuticals Corp.
Supratek Pharma Inc.
CellCentric Ltd.
CureVac GmbH
GenSpera, Inc.
Bind Therapeutics, Inc.
NewLink Genetics Corporation
Bellicum Pharmaceuticals, Inc.
Bostwick Laboratories, Inc.
ATLAB Pharma SAS
DexTech Medical AB
AbbVie Inc.
Sotio a.s.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
enzalutamide - Drug Profile
orteronel - Drug Profile
custirsen sodium - Drug Profile
tasquinimod - Drug Profile
enzalutamide - Drug Profile
cabozantinib (s)-malate - Drug Profile
Prostvac - Drug Profile
DCVAC/PCa - Drug Profile
patupilone - Drug Profile
DI-17-E-6 - Drug Profile
olaratumab - Drug Profile
navitoclax - Drug Profile
vandetanib - Drug Profile
PSMA ADC - Drug Profile
GTx-758 - Drug Profile
linsitinib - Drug Profile
olaparib - Drug Profile
panobinostat - Drug Profile
carfilzomib - Drug Profile
ganetespib - Drug Profile
pelareorep - Drug Profile
PX-866 - Drug Profile
CV-9103 - Drug Profile
G-202 - Drug Profile
docetaxel targeted nanoparticles - Drug Profile
buparlisib hydrochloride - Drug Profile
NLG-8189 - Drug Profile
Adenovirus/PSA Vaccine - Drug Profile
TL-118 - Drug Profile
CV-9104 - Drug Profile
Dendritic Cell Vaccine + [docetaxel] - Drug Profile
ATL-101 - Drug Profile
Anti-PSMA Designer T Cells - Drug Profile
CreaVax-PC - Drug Profile
VDC-2008 - Drug Profile
BPX-101 - Drug Profile
CFG-920 - Drug Profile
Osteodex - Drug Profile
CVA-21 - Drug Profile
RG-7450 - Drug Profile
BPX-201 - Drug Profile
ONC-1-13B - Drug Profile
ES-414 - Drug Profile
Deubiquitinase Program - Drug Profile
cabazitaxel nanoformulation - Drug Profile
Compound 54 - Drug Profile
Cannabinoid Receptors Agonists - Drug Profile
ABS-001 - Drug Profile
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables


Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Exelixis, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Active Biotech AB, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncothyreon Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GenSpera, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bind Therapeutics, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bostwick Laboratories, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H1 2014

List of Figures


Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Upcoming Reports:

Greece: pickles market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the pickles market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the pickles market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Marine Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Marine biotechnology is a growing field comprising marine bio-medicine including pharmaceuticals discovery, materials technology, bio remediation, marine biomedical model organism, genomics, bioinformatics and molecular genetics. The prime motivation for this discipline is clearly derived from the enormous biodiversity and genetic life in sea. The marine environment is a rich source of both chemical and biological diversity. This diversity consists of compound with the potential for industrial development as cosmetics, nutritional supplements, pharmaceuticals, molecular probes,...
2014 Deep Research Report on Global and China EPDM and SSBR Industry
By - QYResearch
2014 Deep Research Report on Global and China EPDM and SSBR Industry

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Keeps High Hopes from Asia Pacific
May 27, 2015  
Ford Motor Company is continuing to make investments heavily in the mainland China, despite the company is getting signs showing a mild slowdown, which has caused the automobile manufacturer to make some small cut in the productions of vehicles. The Asia Pacific president of Ford, David Schoch, has declined to give out any details and of which all models were affected in this mentioned cuts,...
Tata Motors to Face Some Shrink in Profits Figures Due to the Declining Demand of Jaguar Land Rover in China
May 27, 2015  
The quarterly profits of Tata Motors went down, owing to the declining demand for Jaguar Land Rover vehicles in China. On Tuesday, Tata Motors informed that the net income fell around 56% to US$269 million (17.2 billion rupees) in the first quarter that ended in March, from 39.2 billion rupees that was in the previous year. The profits at the Jaguar Land Rover segments went down 33% to...
Changsha Unit of Volkswagen Group Launches Its First Product into the Market
May 27, 2015  
Just a couple of days back, the Volkswagen Group’s recent active production facility launched its very first car off the line. The Changsha plant of Volkswagen is anticipated to boost the production capacity of the German automaker in the Asia Pacific market by around 300,000 units every year. According to the Global Times on 24th of May, a brand new sedan named - Lavida arrived...
China Will Now Have its Own Forrest Gump Restaurant
May 27, 2015  
Last week, the city of Changchun in China witnessed the inauguration of the country’s very own Forrest Gump Restaurant. China is renowned across the globe as the hotbed of the most innovative and quirky restaurants and eateries, and many of them recreate the world of the various television show and film. The country already has a “Friends” themed restaurant that hails its...
Hormel Acquired the Stakes of Applegate Farms
May 27, 2015  
It was recently announced by a spokesperson from Hormel Foods that the company has paid a whopping US$775 million to take over the stakes of the renowned processed meats maker, Applegate Farms. The deal according to many will be the latest one initiated by a market leader to purchase the smaller rivals in the food industry.  When questioned about the reason behind the decision of...